Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when ...

Inari Medical, now part of Stryker, announced the launch of its next-generation InThrill thrombectomy system. According to ...

Globally, strokes affect 15 million individuals annually, resulting in 5 million deaths and leaving another 5 million with ...

InterVene’s Recana has been specifically designed to address the long-term complications associated with chronic venous ...

Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when blood flow is restored following a stroke.

Key Points Penumbra topped analyst forecasts with $339.5 million in GAAP revenue and $0.86 non-GAAP EPS, driven by double-digit U.S. thrombectomy growth. Gross margin (GAAP) expanded sharply to 66.0%, ...

Catheter system designed to treat blocked or damaged leg veins that have previously been stented and fail to return blood ...

A potentially life-saving stroke treatment will be on offer around the clock in Lancashire by early next year at the latest, ...

The benefit of thrombolysis plus thrombectomy decreased with longer times from symptom onset to expected administration of thrombolysis; adjusted common odds ratio for a 1-step modified Rankin ...

Explore Penumbra's Q2 2025 earnings highlights, featuring 13.4% growth, U.S. thrombectomy success, RUBY XL launch insights, and updated revenue guidance.

Inari Medical — now part of Stryker (NYSE: SYK) + — today announced the launch of its next-generation InThrill thrombectomy system. The company describes InThrill as the first and only purpose-built ...